Search
for
Sort by
Research 61–90 of 81
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Sorafenib stimulates human skin type mast cell degranulation and maturation
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Prophylaxis and Management of Skin Toxicities
- Treatment of Chemotherapy Induced Alopecia
- Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens
- Therapies and nanotherapies for cervical cancer (Review)
- Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
- Gastric cancer; actualities and perspectives of early diagnosis and targeted therapy
- Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets
- Transcriptome-guided development of a fibrosis-reversal compound reduces skin scarring and allows regeneration via mitochondrial uncoupling
- The possibilities of correction of premature greying of hair and involutive hair changes
- Millets as a dietary supplement for managing chemotherapy induced side effects
- Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)
- Alopecia in a Viable Phospholipase C Delta 1 and Phospholipase C Delta 3 Double Mutant
- A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
- Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Cutaneous adverse effects of targeted therapies
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Sorafenib-Associated Facial Acneiform Eruption
- Case of alopecia induced by sorafenib, possible mechanism similar to alopecia areata
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)